期刊文献+

脂蛋白相关磷脂酶A2在冠状动脉粥样硬化性心脏病患者中的临床应用价值 被引量:10

Clinical application value of serum lipoprotein associated phospholipaseA2 in coronary atherosclerotic heart diseases
暂未订购
导出
摘要 目的探讨血清脂蛋白相关磷脂酶A2(Lp-PLA2)在冠状动脉粥样硬化性心脏病(CAD)的临床应用价值。方法采用病例对照研究,选取2013年10月至2015年6月在该院进行冠状动脉CT血管造影(CTA)检查的患者790例,根据冠状动脉CTA结果分为CAD组(352例)和无CAD对照组(438例),CAD组依据冠状动脉病变支数不同分为单支冠状动脉病变(118例)、双支冠状动脉病变(107例)和多支冠状动脉病变(132例),检测Lp-PLA2、超敏C反应蛋白(hs-CRP)、三酰甘油(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、葡萄糖(GLU)、糖化血红蛋白A1c(HbA1c)等指标进行综合分析。各组均数比较采用t检验或方差分析;不同指标相关性采用Pearson直线相关分析。结果 CAD组和对照组比较,LpPLA2、hs-CRP、年龄、GLU、HbA1c、载脂蛋白B(ApoB)水平CAD组均明显高于对照组,差异均有统计学意义(均P<0.05)。LpPLA2在CAD组不同冠状动脉病变支数间比较,差异有统计学意义(F=4.941,P<0.05);多支冠状动脉病变组Lp-PLA2水平高于单支冠状动脉病变组,差异有统计学意义(P<0.05);多支冠状动脉病变组和双支冠状动脉病变组Lp-PLA2水平差异无统计学意义(P>0.05);双支冠状动脉病变组和单支冠状动脉病变组Lp-PLA2水平差异无统计学意义(P>0.05)。Lp-PLA2和HsCRP之间用Pearson直线相关分析,结果显示无相关性(r=0.042,P>0.05)。结论血清Lp-PLA2水平升高是CAD的危险因素,可用于冠状动脉粥样硬化及受累血管支数的风险评估。 Objective To investigate the clinical application value of serum lipoprotein associated phospholipase A2(Lp‐PLA2) in coronary atherosclerotic heart diseases(CAD) .Methods Using the case‐control study ,790 patients with coronary computed tomography angiography (CTA) in our hospital from October 2013 to June 2015 were selected and divided into the CAD group (352 cases) and control group (438 cases) according to the results of coronary artery CTA .According to the number of coronary artery lesion vessels the CAD group was re‐divided into three subgroups :single branch coronary artery lesion (118 cases) ,double branch coronary arterial lesions(n=107) and multiple branch coronary arterial lesions(132 cases) .The levels of Lp‐PLA2 ,hs‐CRP , TG ,TC ,HDL‐C ,LDL‐C ,glucose ,HbA1c and other indexes were measured and comprehensively analyzed .The t test or variance a‐nalysis was used to compare the means between or among groups .The correlation of different indicators was analyzed with the Pearson linear correlation analysis .Results Compared with the control group ,the CAD group was significantly higher than the con‐trols in the levels of Lp‐PLA2 ,hs‐CRP ,age ,GLU ,HbA1c and ApoB ,the differences were statistically significant(P〈0 .05) .The Lp‐PLA2 level had statistical difference among different branch coronary artery lesions in the CAD group(F=4 .941 ,P〈0 .05) ,the level of Lp‐PLA2 in the CAD group with multiple branch coronary artery disease was higher than that in single branch coronary ar‐tery disease(P〈0 .05) .No statistically significant difference between multiple branch coronary artery disease and double branch coronary arteries disease was observed .No statistically significant difference between double branch coronary arteries disease and single branch coronary artery disease was observed .The Pearson linear correlation analysis showed that Lp‐PLA2 and hs‐CRP had no correlation (r=0 .042 ,P〉0 .05) .Conclusion Serum Lp‐PLA2 level increase is a risk factor of CAD and could be used to assess coronary arterial atherosclerosis and number of coronary arterial lesions .
出处 《国际检验医学杂志》 CAS 2016年第16期2247-2249,共3页 International Journal of Laboratory Medicine
关键词 冠状动脉粥样硬化性心脏病 脂蛋白相关磷脂酶A2 冠状动脉CT血管造影 coronary atherosclerotic heart disease coronary computed tomography angiography
  • 相关文献

参考文献14

  • 1Epstein FH, Ross R. Atherosclerosis-an inflammatory disease[J]. N Engl J Med,1999,340(2) :115-126.
  • 2Libby P,Ridker PM, Maseri A. Inflammation and athero-sclerosis[J]. Circulation,2002,105(9) : 1135- 1143.
  • 3Yang EH, Mceonnell JP, Lennon RJ, et al. Lipoproteiwas- soeiated phospholipase A2 is an Independent marker for coronary endothelial dysfunction in humansFJ]. Arterio- scler Thromb Vase Biol,2006,26(1):106-111.
  • 4刘甲兴,郑兴.脂蛋白相关磷脂酶A2与动脉粥样硬化[J].中国动脉硬化杂志,2006,14(3):274-276. 被引量:14
  • 5Goncalves I, Edsfeldt A, Ko NY, et al. Evidence support- ing a key role of Lp-PLA2-generated lysophosphatidyi- choline in human atherosclerotic plaque inflammationFJ]. Arterioscler Thromb Vasc Biol,2012,32(6):1505-1512.
  • 6Cai A, Li G, Chen J, et al. Increased serum level of Lp- PLA2 is independently associated with the severity of cor- onary artery diseases: a cross-sectional study of Chinese population[J]. BMC Cardiovasc Disord, 2015,15 ( 1 ) : 14- 16.
  • 7Dohi T, Miyauchi K, Ohkawa R, et al. Higher lipoprotein- associated phospholipase A2 levels are associated with coronary atherosclerosis documented by coronary angiog- raphy[J]. Ann Clin Biochem, 2012,49 (Pt 6) : 527-533.
  • 8Vittos O, Toana B, Vittos A, et al. Lipoproteir associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker[J]. Biomark- ers, 2012,17 (4) : 289-302.
  • 9邬建民,张力.脂蛋白相关磷脂酶A2在冠心病患者严重程度评估中的应用[J].检验医学,2011,26(2):85-87. 被引量:22
  • 10Schmidt EB, Koenig W, Khuseyinova N, et al. Lipopro- tein-assoeiated phospholipase A2 concentrations in plas- ma are associated with the extent of coronary artery dis- ease and correlate to adipose tissue levels of marine n-3 fatty acids[J]. Atherosclerosis, 2008,196 (1) : 420-424.

二级参考文献35

  • 1Lp-PLA(2) Studies Collaboration,Thompson A,Gao P,et al.Lipoprotein-associated phospholipase A(2) and risk of coronary disease,stroke,and mortality:collaborative analysis of 32 prospective studies[J].Lancet,2010,375(9725):1536-1544.
  • 2Gensini GG.A more meaningful scoring system for determining the severity of coronary heart disease[J].Am J Cardiol,1983,51(3):606.
  • 3Sachdeva A,Cannon CP,Deedwania PC,et al.Lipid levels in patients hospitalized with coronary artery disease:an analysis of 136,905 hospitalizations in get with the guidelines[J].Am Heart J,2009,157(1):111-117.
  • 4Kolodgie FD,Burke AP,Skorija KS,et al.Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis[J].Arterioscler Thromb Vasc Biol,2006,26(11):2523-2529.
  • 5Packard CJ,O′Reilly DS,Caslake MJ,et al.Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease[J].N Engl J Med,2000,343(16):1148-1155.
  • 6Brilakis ES,McConnell JP,Lennon RJ,et al.Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors,angiographic coronary artery disease,and major adverse events at follow-up[J].Eur Heart J,2005,26(2):137-144.
  • 7Libby P. Inflammation and atherosclerosis[J]. Circulation,2002,105(9):1135-143
  • 8Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease[J]. Atherosclerosis, 2000, 150(2):413-419
  • 9Cao Y, Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM. Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation[J]. J Biol Chem, 1998, 273(7):4012-020
  • 10Tselepis AD, Karabina SA, Stengel D, Piedagnel R, Chapman MJ, Ninio E. N-linked glycosylation of macrophagederived Lp-PLA2 is a major determinant of enzyme association with plasma HDL[J]. J Lipid RES, 2001, 42(42):1645-654

共引文献117

同被引文献73

引证文献10

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部